

Table S1. Comparison of Primary Outcomes between Subgroups with and without PLA₂R-associated Treatment

Primary Outcomes	PLA ₂ R-associated ^a (n=30)	non-PLA ₂ R-associated (n=4)	<i>P</i>
Total obinutuzumab dose during follow-up,g, median(IQR)	2.0(1.72-2.22)	2.17(0.91-4.09)	0.18
Time to first remission,mo,mean±SD	7.23±4.82	5.45±4.91	0.5
First relapse-free survival time during follow-up,	5.55±4.51	8.21±4.51	0.31
Remission rate during follow-up,n(%)	28(93.3%)	4(100%)	0.78
Partial remission rate during follow-up,n(%)	18(60%)	3(75%)	0.5
Complete remission rate during follow-up,n(%)	10(33.3%)	1(25%)	0.61
Remission rate in 6,n(%)	14(46.7%)	2(50%)	0.65
Remission rate in 12,n(%)	23(76.7%)	4(100%)	0.38

Abbreviation:IQR,interquartile range.

^aSerum anti-PLA₂R antibody titer and(or) renal tissue PLA₂R staining are positive.